The estimated Net Worth of Jesse I Treu is at least $28.4 Milión dollars as of 26 March 2019. Jesse Treu owns over 96,743 units of Aldeyra Therapeutics Inc stock worth over $54,243 and over the last 21 years he sold ALDX stock worth over $28,219,786. In addition, he makes $139,538 as Independent Director at Aldeyra Therapeutics Inc.
Sign up
Jesse Treu ALDX stock SEC Form 4 insiders trading
Jesse has made over 11 trades of the Aldeyra Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 96,743 units of ALDX stock worth $968,397 on 26 March 2019.
The largest trade he's ever made was buying 3,500,000 units of Aldeyra Therapeutics Inc stock on 16 September 2011 worth over $7,000,000. On average, Jesse trades about 246,388 units every 121 days since 2004. As of 26 March 2019 he still owns at least 8,763 units of Aldeyra Therapeutics Inc stock.
You can see the complete history of Jesse Treu stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jesse Treu biography
Dr. Jesse I. Treu Ph.D. serves as Independent Director of the Company. Dr. Treu has served on our Board of Directors since June 2013. Dr. Treu was a founding partner of Domain Associates, L.L.C. and became Partner Emeritus in 2018. He has been a director of over 38 early-stage healthcare companies. Dr. Treu currently serves as a member of the board of directors of Sebacia, Inc. He has also served as a founder, president and chairman of numerous venture-stage companies. Prior to the formation of Domain Associates, Dr. Treu had twelve years of experience in the healthcare industry. He was Vice President of the predecessor organization to The Wilkerson Group and its venture capital arm, CW Ventures. While at CW Ventures, he served as President and CEO of Microsonics, Inc., a pioneer in computer image processing for cardiology. Previous to that, Dr. Treu led new product development and marketing planning for immunoassay and histopathology products at Technicon Instruments Corporation, which is now part of Siemens Medical Solutions Diagnostics. Dr. Treu began his career with General Electric Company in 1973, initially as a research scientist developing thin film optical sensors for immunoassay testing, and later serving on the corporate staff with responsibility for technology assessment and strategic planning. Dr. Treu received his B.S. in Physics from Rensselaer Polytechnic Institute and his M.A. and Ph.D. in physics from Princeton University. Dr. Treu's extensive knowledge of our business and history, experience as a board member of multiple publicly-traded and privately-held companies and expertise in developing and financing contributed to our conclusion that he should serve as a director of our company.
What is the salary of Jesse Treu?
As the Independent Director of Aldeyra Therapeutics Inc, the total compensation of Jesse Treu at Aldeyra Therapeutics Inc is $139,538. There are 7 executives at Aldeyra Therapeutics Inc getting paid more, with Todd Brady having the highest compensation of $4,141,260.
How old is Jesse Treu?
Jesse Treu is 73, he's been the Independent Director of Aldeyra Therapeutics Inc since 2013. There are no older and 14 younger executives at Aldeyra Therapeutics Inc.
What's Jesse Treu's mailing address?
Jesse's mailing address filed with the SEC is C/O DOMAIN ASSOCIATES, LLC, 202 CARNEGIE CENTER, SUITE 104, PRINCETON, NJ, 08540.
Insiders trading at Aldeyra Therapeutics Inc
Over the last 11 years, insiders at Aldeyra Therapeutics Inc have traded over $6,285,725 worth of Aldeyra Therapeutics Inc stock and bought 11,547,153 units worth $75,179,936 . The most active insiders traders include Advisors Llcperceptive Life..., & Johnson Johnson & Johnson... a Advisors Llcedelman Josephp.... On average, Aldeyra Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $1,358,662. The most recent stock trade was executed by Stephen Machatha on 12 August 2024, trading 16,041 units of ALDX stock currently worth $76,034.
What does Aldeyra Therapeutics Inc do?
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
What does Aldeyra Therapeutics Inc's logo look like?
Complete history of Jesse Treu stock trades at Aldeyra Therapeutics Inc, Alimera Sciences, Clovis Oncology Inc, Dicerna Pharmaceuticals Inc, Esperion Therapeutics, Evoke Pharma Inc, Nuvasive Inc, Tandem Diabetes Care Inc, Vanda Pharmaceuticals Inc, Veracyte Inc a Zogenix Inc
Aldeyra Therapeutics Inc executives and stock owners
Aldeyra Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Todd Brady,
President, Chief Executive Officer, Director -
Joshua Reed,
Chief Financial Officer -
David McMullin,
Chief Commercial Officer -
Dr. Todd C. Brady M.D., Ph.D.,
CEO, Pres & Director -
Joshua Reed M.B.A.,
Chief Financial Officer -
Richard Douglas,
Independent Chairman of the Board -
Martin Joyce,
Independent Director -
Jesse Treu,
Independent Director -
Ben Bronstein,
Independent Director -
Gary Phillips,
Independent Director -
Neal Walker,
Independent Director -
Scott Solomon,
IR Contact Officer -
Nancy Miller-rich,
Independent Director -
Stephen Machatha,
Senior Vice President, Technical Operations -
James Gow,
Senior Vice President - Clinical Development -
Bruce Greenberg CPA, M.B.A.,
VP & Controller -
Dr. Stephen G. Machatha Ph.D.,
Chief Devel. Officer -
Kelly Mizer,
VP of Commercial Strategy & Operations -
David J Clark,
Chief Medical Officer -
Advisors Llcedelman Josephp...,
-
C. Boyd Clarke,
Director -
Stephen J Tulipano,
Chief Financial Officer -
Scott Young,
Chief Operating Officer -
Bruce Greenberg,
See Remarks -
Advisors Llcperceptive Life...,
-
Partners Vi, L.P.Blair Jame...,
-
& Johnson Johnson & Johnson...,
-
Vi Associates, L.P.Blair Ja...,